Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight Hopes 2011 Didn’t Set A (Low) Fundraising Benchmark For 2012

This article was originally published in The Pink Sheet Daily

Executive Summary

Plus news on recent financings by Warp Drive Bio, Synageva BioPharma, Elevation Pharmaceuticals and Acceleron Pharma.


Related Content

Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio
With $30 Million Series B In Hand, Elevation Prepares To Take Inhalable COPD Drug Up To Phase III
Shire And Atlas Venture To Work Together To Incubate Rare Disease Research Projects
Celgene Partners With Acceleron On Novel Bone Forming Compound


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts